Pyridopyrimidines as Anticancer Agents

Abstract

The main purpose of this review is to provide an overview of the current knowledge for development of new molecules of pyridopyrimidines by using different multi-component reactions that lead to give effective anticancer agents. Thus, the developed compounds have been derived from pyridine and pyrimidines fusion or from possible isomeric forms of pyridopyrimidine derivatives. They are obtained from different approaches of multistep synthesis reaction such as Tandemaza-witting reaction, annulations, and Biginelli type reactions. Apart from the synthetic schemes, their biological applications with an alternative mechanism of action, such as growth inhibitors by cell cycle arrest, apoptosis, inhibition of angiogenesis, disruption of cell migration, and mutation, are also understood. These receptors and enzymes are responsible for causes of cancer because disruptions of dihydrofolate reductase, tyrosine kinase, cyclin-dependent kinase-4 and 6, and fibroblast growth factor receptor. Among heterocyclic compounds, pyridopyrimidine compounds are privileged structure in medicinal chemistry, especially with FGFR-TK, CDK-4, ABCG-2, Ef-2 kinase, and Type-II pan-RAF kinase inhibitors (Figure 1). The present review illustrates that pyridopyrimidines have been developed by using new strategies and may be utilized for treatment of various cancer.